Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07670884
PHASE3

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

425

Start Date

2026-07

Completion Date

2027-08

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

HRS9531 Tablet

HRS9531 tablet.

DRUG

HRS9531 Tablet Placebo

HRS9531 tablet placebo.

Locations (2)

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Nanjing Drum Tower hospital

Nanjing, Jiangsu, China